1. Home
  2. Studies
  3. CDT : Clinical Studies (index)
scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.
 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

A 6-months prospective, observational study to evaluate the quality of life of patients treated with phytotherapy or alpha-blockers for benign prostatic hyperplasia.

 		Urology RWE Active June 2022 February 2024

Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors. International, multicenter, open label study.

 		Oncology Phase I / II Active 24 November 2017 04 October 2021

A randomized, single-center, open-label, single dose, two-period, crossover pivotal bioequivalence study comparing binimetinib 3 x 15 mg and 45 mg tablets in healthy participants

 		Oncology Phase I Active 31 August 2022 December 2022

Phase 2, open-label, single arm, multicenter study of Encorafenib, Binimetinib plus Cetuximab in subjects with previously untreated BRAFV600E -mutant metastatic colorectal cancer

 		Oncology Phase II Active not recruiting 14 January 2019 March 2023

A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants

 		Oncology Phase I Active not recruiting 03 September 2021 19 November 2021
1 - 5 over 126

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

Phase III  -  COLUMBUS

SPONSOR: PFIZER

Breast cancer 

Phase III    -    EXTENET

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

Phase III - BEACON CRC

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

Phase III     -       ALLELE

SPONSOR: ATARA

 

 

 

 

Studies status

Lorem ipsum dolor

Sed hendrerit lorem augue, at molestie ligula dapibus id. Phasellus eu ullamcorper diam.

Lorem ipsum dolor

Sed at augue ut ex tempor congue convallis sed orci. Suspendisse congue pellentesque velit non convallis. Integer nec risus eu urna finibus ornare nec nec eros.

Lorem ipsum dolor

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nulla dapibus id dolor placerat gravida.

Lorem ipsum dolor

Integer vel tortor sapien. Nulla elit tellus, interdum vitae lobortis id, scelerisque nec elit. Donec ut maximus nibh. Nunc sit amet nibh nec leo scelerisque tempus id sed nisi. Duis vehicula sem sit amet elit cursus, nec ultrices turpis cursus.

Lorem ipsum dolor

Donec eget ultrices justo. Donec posuere, nibh quis dignissim feugiat, ante turpis pharetra sapien, vel faucibus magna leo eu quam. Fusce sed massa sapien.

Lorem ipsum dolor

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nulla dapibus id dolor placerat gravida.

Lorem ipsum dolor

Nunc congue diam metus, id hendrerit nulla fringilla non. Nullam non interdum dui. Phasellus quis dapibus erat. Aliquam metus ipsum, luctus nec mollis vitae, varius ut massa.